NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

It's not the only anomaly. On the Top 100, it is stated on Slide 24, that 75% had a complete resection. On the next slide, it is 71%...
Not of any huge significance, but it's the sort of anomaly that they really need to avoid in the official trial outcome stats.
The AF's of the world will pore all over the final readouts, looking for any anomalies; so as to cast any doubt that they can on the data.

Interim data March 2017-Top 100: 71% had a complete resection.

Unknown factors: sub-group with extended survival
Approximately 30% of the ITT population (n?=?100) showed particularly extended survival, with a KM derived mOS estimate of 40.5 months. This is not fully explained by known prognostic factors, as only some of these patients had positive prognostic factors: only 29% were younger than 50 years of age, 65.9% had methylated MGMT, 71% had a complete resection, and only 8% of these patients had all three positive prognostic factors. These patients will be the subject of extensive further analyses and research.
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6#Abs1

I think Dr. Marnix Bosch used the same 2018 slide in his December 2019 update presentation, but forgot to correct that number of complete resection.
2018 presentation

2019: slide 25
https://nwbio.com/wp-content/uploads/Boston-Presentation-v0.2.pdf